Floatz logo

Visilizumab

Refractory Leukemia

The First Affiliated Hospital of Soochow Universitymonoclonal_antibodyPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

125 Active assets in the Refractory Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

Visilizumab is also rated in:

ImmunotherapyDormant
CCC
Indicative ·
54 / 100
View asset →
graft versus host diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →